Branimir Ivan Sikic

US Patent:

7875274, Jan 25, 2011

Filed:

Dec 13, 2006

Appl. No.:

11/638161

Inventors:

Branimir Sikic - Stanford CA, US
Markus Bredel - Evanston IL, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 48/00
C12Q 1/68

US Classification:

424 9321, 435 6, 977802

Abstract:

There is disclosed a method for identifying a therapeutically responsive phenotype, as distinguished, e. g. from an alkylating agent resistant phenotype in a cell, which method may be used to evaluate the likelihood of successful outcome of treating a tumor cell with an alkylating agent. The method is directed to the NF-κB activation in response to DNA damage caused by alkylating agents. It comprises the step of measuring a level of expression of a protein, which participates in the NF-κB pathway. Preferably it comprises measuring the expression of TNFAIP3 in the cell, wherein a resistant phenotype has less expression of TNFAIP3 than a sensitive phenotype. Another particularly significant gene, which predicts survival, is NFKBIA. Other genes whose altered expression level is associated with resistance or prognosis are TNIP1, TNIP2, RIP, NFKBIB, Beta4GalNAc-T4, NFKBIE, C8orf4, LIF, CD44, FBXO32, and SDC1, and these are also measured in certain embodiments.

US Patent:

20070009531, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/416833

Inventors:

Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 39/395
A61K 31/4709

US Classification:

424155100, 424178100, 514314000

Abstract:

The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such as Mylotarg. The invention is also directed to pharmaceutical formulations comprising zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML) and metastatic breast cancer.

US Patent:

20070009532, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/416992

Inventors:

Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 39/395
A61K 31/4709

US Classification:

424155100, 424178100, 514314000

Abstract:

The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such as Mylotarg. The invention is also directed to pharmaceutical formulations comprising zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML) and metastatic breast cancer.

US Patent:

20070009533, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/417984

Inventors:

Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 39/395
A61K 38/13
A61K 31/553
A61K 31/551
A61K 31/455
A61K 31/4709
A61K 31/704
A61K 31/277
A61K 31/138

US Classification:

424155100, 514220000, 514011000, 514026000, 514263320, 514317000, 514469000, 514253040, 514389000, 514291000, 514225800, 514314000, 514355000, 514211070, 514521000, 514651000

Abstract:

The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.

US Patent:

20070009534, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/418323

Inventors:

Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glen - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 39/395
A61K 31/704
A61K 31/7048
A61K 31/4709
A61K 31/4745
A61K 31/337

US Classification:

424155100, 424178100, 514314000, 514283000, 514449000, 514034000, 514027000

Abstract:

The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.

US Patent:

20070009535, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/418399

Inventors:

Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 39/395
G01N 33/574
A61K 31/704
A61K 31/525
A61K 31/4745
A61K 31/4709

US Classification:

424155100, 435007230, 424178100, 514314000, 514251000, 514283000, 514034000, 514410000

Abstract:

The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.

US Patent:

20070010465, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/416571

Inventors:

Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 31/704
A61K 31/4709
A61K 31/4745
A61K 31/337

US Classification:

514034000, 514314000, 514283000, 514449000

Abstract:

The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML).

US Patent:

20070010466, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/416832

Inventors:

Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 31/7072
A61K 31/704
A61K 31/4709

US Classification:

514034000, 514049000, 514314000

Abstract:

The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML).